Dosavadní zkušenosti s léčbou ropeginterferonem alfa-2b u pacientů s Ph negativními myeloproliferacemi na Interní hematologické a onkologické klinice LF MU a FN Brno

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine – Haematology and Oncology in Brno
Authors

PODSTAVKOVÁ N. WEINBERGEROVÁ Barbora PROCHÁZKOVÁ Jiřina BOHÚNOVÁ Michaela MAREČKOVÁ Andrea KOTAŠKOVÁ Jana JEŽÍŠKOVÁ Ivana DOUBEK Michael MAYER Jiří

Year of publication 2022
Type Article in Periodical
Magazine / Source Transfuze a Hematologie Dnes
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/2022-4-18/dosavadni-zkusenosti-s-lecbou-ropeginterferonem-alfa-2b-u-pacientu-s-ph-negativnimi-myeloproliferacemi-na-interni-hematologicke-a-onkologicke-klinice-lf-mu-a-fn-brno-133047
Doi http://dx.doi.org/10.48095/cctahd2022prolekare.cz15
Keywords polycythemia vera; Ph negative myeloproliferative neoplasms; ropeginteferon alpha-2b
Attached files
Description Background: Ropeginterferon alfa-2b demonstrated efficacy and safety in patients with polycythaemia vera in the PROUD-PV and CONTINUATION-PV multicentric randomised studies. These studies reported the superior effect of ropeginterferon alfa-2b in attaining haematological and molecular remission during the fourth and fifth year of therapy. Patients and Methods: A total of 14 Ph-MPN patients treated with ropeginterferon alfa-2b at our Dept. of Internal Medicine – Haematology and Oncology were analysed from May 2020 to July 2022. Therapy duration, dosing, effect, and tolerance were evaluated. Results: Therapy median duration was 266 days. 14 patients in total were treated; 11 had polycythaemia vera (79%), 2 had essential thrombocythemia (14%), and one patient had secondary myelofibrosis post polycythaemia vera (7%). The median ropeginterferon alfa 2-b dose was 150 µg. Complete haematological remission was attained in 11 (79%) patients. Two patients (14%) had to discontinue treatment. During therapy, six patients (43%) suffered adverse events; only one patient (7%) developed a thromboembolic event. Conclusion: Our initial experience has confirmed the promising effect of ropeginterferon alfa 2-b on haematocrit control and its excellent tolerance among patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.